Supernus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SUPN Supernus Pharmaceuticals Inc
GOOD Gladstone Commercial Corp
ADTN ADTRAN Inc
ALRM Alarm.com Holdings Inc
NLOK NortonLifeLock Inc
PROSY Prosus NV
IMBBY Imperial Brands PLC
VNTR Venator Materials PLC
HOLX Hologic Inc
DMTK DermTech Inc
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Price
Delayed
$25.97
Day's Change
-0.90 (-3.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.70
Day's Low
25.64
Volume
(Heavy Day)

Today's volume of 703,966 shares is on pace to be much greater than SUPN's 10-day average volume of 568,596 shares.

703,966

Thinking about buying stock in Ocugen, Kopin Corp, Mogo Inc, Supernus Pharmaceuticals, or eMagin Corp?

8:30 am ET December 23, 2020 (PR Newswire) Print

InvestorsObserver issues critical PriceWatch Alerts for OCGN, KOPN, MOGO, SUPN, and EMAN.

https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

-- OCGN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=OCGN&prnumber=122320201

-- KOPN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=KOPN&prnumber=122320201

-- MOGO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MOGO&prnumber=122320201

-- SUPN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=SUPN&prnumber=122320201

-- EMAN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=EMAN&prnumber=122320201

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

https://c212.net/c/img/favicon.png?sn=CG32731&sd=2020-12-23

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-ocugen-kopin-corp-mogo-inc-supernus-pharmaceuticals-or-emagin-corp-301198088.html

SOURCE InvestorsObserver

https://rt.prnewswire.com/rt.gif?NewsItemId=CG32731&Transmission_Id=202012230830PR_NEWS_USPR_____CG32731&DateId=20201223

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.